ArticleDermatology reports2026
Microinfusion of medications into the skin as a drug delivery technique: a narrative review.
Article in Dermatology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microinfusion of medications into the skin (MMP®) is an innovative method that employs tattoo devices to administer pharmaceuticals transdermally. This technique facilitates the formation of microchannels in the skin, allowing for localized drug deposition with minimal systemic absorption and fewer adverse effects. A literature search was conducted using PubMed and Google Scholar to identify studies discussing the application of MMP as a transdermal drug delivery method, covering publications up to October 2025. All studies identified through the literature search were summarized in chronological order from the earliest (2013) to the most recent (2025). This arrangement was chosen to illustrate the progressive evolution of the MMP technique and its expanding clinical applications over time. Our research found 14 studies that evaluated the effectiveness of the tattoo machine for transdermal drug administration. Eight studies focused on MMP for alopecia treatments, demonstrating notable improvements in androgenetic alopecia, alopecia areata, and frontal fibrosing alopecia, with minimal adverse reactions reported. Six studies investigated its role in treating scars and striae, showing significant lesion improvement. One study examined its use with bleomycin in basal cell carcinoma treatment, and another assessed its impact on psoriasis vulgaris with cyclosporine A and methotrexate (MTX). MMP represents a promising, minimally invasive transdermal delivery system with a growing body of evidence supporting its application in alopecia, oncologic dermatology, and pigmentary disorders. The ability to uniformly distribute medications at targeted skin depths, combined with its favorable safety profile, highlights its potential as a valuable alternative to conventional delivery methods. Furthermore, the microneedling effect of the tattoo device itself may confer therapeutic benefits independent of pharmaceutical administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.